Abstract:
Introduction: Prostate epithelial cells exhibit unique biochemical specialization, accumulating high
levels of zinc (Zn) to inhibit mitochondrial aconitase (m-aconitase) and facilitate citrate secretion.
During malignancy, zinc dyshomeostasis triggers metabolic rewiring, reactivating the tricarboxylic
acid (TCA) cycle to fuel tumor progression. For tissue transplantation and engineering, understanding
these zinc-dependent metabolic signatures is essential for developing biomimetic scaffolds and
regenerative strategies aiming to restore cellular homeostasis and prevent recurrence post-oncological
resection.
Materials and Methods: To evaluate the biochemical dynamics of Zn in prostatic tissue, data were
aggregated from experimental studies analyzing mitochondrial extract preparations derived from rat
ventral prostate models. The analysis prioritized the stoichiometric shift of the citrate/isocitrate ratio
at equilibrium under the inhibitory influence of 7-10 micromolar (μM) concentrations of Zn. Research
was synthesized through a comparative analysis of primary sources retrieved from the National Center
for Biotechnology Information (NCBI) PubMed, ResearchGate, and Google Scholar, covering 1998
to 2025.
Results: This framework allowed for an in-depth assessment of the inhibitory kinetics of mitochondrial
aconitase (m-aconitase) and the functional downregulation of the zinc-regulated, iron-regulated
transporter-like protein 1 (ZIP1). These metabolic trends were subsequently mapped against cellular
bioenergetics in prostate cancer to establish their clinical relevance for tissue engineering and postresection regenerative medicine. Findings demonstrate that 7-10 micromolar (μM) Zn maintains a
unique 13.5:1 citrate/isocitrate ratio by inhibiting mitochondrial aconitase (m-aconitase), a process
mediated by a mitochondrial "citrate factor protein". In prostate cancer, the downregulation of zincregulated, iron-regulated transporter-like protein 1 (ZIP1) causes a 60-80% intracellular zinc depletion.
This loss reactivates the tricarboxylic acid (TCA) cycle and oxidative phosphorylation, providing the
bioenergetic fuel necessary for tumor progression.
Conclusions: The investigation underscores that the zinc-regulated, iron-regulated transporter-like
protein 1 (ZIP1) and mitochondrial aconitase (m-aconitase) regulatory axis is fundamental for
preserving prostatic metabolic homeostasis. Since Zn depletion acts as a critical metabolic switch for
prostate cancer progression, targeting this pathway offers significant therapeutic potential. Future
research should prioritize the development of zinc-enriched biomimetic scaffolds in tissue engineering.
Such regenerative strategies could effectively restore cellular stability and minimize the risk of
malignant recurrence following post-oncological transplantation.
